Advantages of MB3D+
Publication of a clinical study on the
advantages ofMont-Blanc 3D+ in the treatment of
scoliosis
Spineway, specialized in the treatment
of severe disorders of the spine, announces the publication of a
scientific article in the renowned scientific journal Spine
Deformity1 highlighting the benefits of the Mont-Blanc 3D+
technology for the treatment of adolescent idiopathic
scoliosis.
An international clinical study of 49
patientsThis clinical study carried out by Professor
Carlos Barrios (Université Catolique de Valencia, Spain) covered
four countries and involved post-operative follow-up of an average
of 32 months by surgeons Dr. José Lajara (Spain), Dr. Philippe
Mazeau (France), Dr. Karen Weissmann (Chile), Dr. Guahua Lu
(China), Dr. Bing Wang (China), Dr. Lei Kuang (China), Dr.
Yong Hai (China) and Dr. José I. Maruenda (Spain).
This multicentric group provided the clinical
data on 49 patients suffering from adolescent idiopathic scoliosis
and, in particular, studied the restoration of thoracic kyphosis
(curvature in the middle of the spine) in patients after corrective
surgery.
The article, written by Professor Carlos
Barrios, concludes that the use of Spineway’s Mont-Blanc 3D+
instruments provides a better correction of thoracic kyphosis based
on vertebral co-planar alignment than the other methods and
instruments used for comparison in the study.
Restoration of the thoracic spine’s
natural curvesCurrent techniques using pedicle screws have
successfully corrected the spinal deformation of scoliosis patients
from a “frontal view” without, however, restoring the thoracic
spine’s natural curves from a “sagittal view.” These effective
alignment methods unfortunately often result in patients having
“flat backs.”
The natural thoracic curve plays a part in the
body’s overall balance and failure to reconstruct this natural
curve creates long-term problems (pain, compensatory deformation in
the cervical spine causing vision problems, balance, etc.) that are
currently the subject of many publications and communications.
The corrective technique provided by Spineway’s
Mont-Blanc 3D+ instruments allows for “frontal-view” restoration of
a deformed spine as well as “sagittal view” restoration of a
patient’s thoracic curve in a way that is controlled by the
surgeon. This three-dimensional correction of the vertebrae thus
protects the patient from possible long-term adverse effects.
Stéphane Le Roux, Chairman and CEO of Spineway,
said, “We are happy and proud of this article that is the fruit of
collaborative work that began over five years ago with top surgeons
specialized in the treatment of scoliosis. The results obtained in
these different countries confirm the Group’s ability to offer
innovative instruments and implants for the spine. It shows
Spineway’s ongoing desire to provide solutions that contribute to
the improvement of care for patients with disorders of the spine. I
would like to thank all the surgeons who participated in this study
for their trust and participation.”
This article shows the quality of the
Mont Blanc 3D+ instruments developed and patented by Spineway, and
the progress this means for patients’ everyday comfort, as well as
for the surgeons’ operating technique.
Upcoming: 27 October 2020 – 2020 half-year
results
SPINEWAY IS ELIGIBLE FOR THE PEA-PME
(EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at
www.spineway.com
This press release on July 22, 9 am has been
prepared in both English and French. In case of discrepancies, the
French version shall prevail.
Spineway
designs, manufactures and markets innovative implants and surgical
instruments for treating severe disorders of the spinal
column.
Spineway has
an international network of over 50 independent distributors and
90% of its revenue comes from exports.
Spineway,
which is eligible for investment through FCPIs (French unit trusts
specializing in innovation), has received the OSEO Excellence award
since 2011 and has won the Deloitte Fast 50 award (2011). Rhône
Alpes INPI Patent Innovation award (2013) – INPI Talent award
(2015).
ISIN:
FR0011398874 - ALSPW
Contacts:
Spineway Shareholder-services line Available
Tuesday through Thursday (10 a.m. – 12 p.m.) +33 (0)811 045
555 |
Eligible PEA/PMEALSPWEuronext Growth |
AELIUM Finance & Communciation Investor
relations Solène Kennis spineway@aelium.fr |
1
https://link.springer.com/article/10.1007%2Fs43390-020-00067-8
Grafico Azioni Spineway (EU:ALSPW)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Spineway (EU:ALSPW)
Storico
Da Apr 2023 a Apr 2024